Front > MARKET


Ishay Davidi Photo: Eyal Yitzhar FIMI mulls TASE IPO for security co G1

FIMI recently met with major investment institutions to test the feasibility of selling its holding in G1, formerly G4S, on the TASE.

Teva Photo: ASAP Creative Shutterstock Analysts soothe on Teva's migraine drug snub

Teva's Ajovy may have been rejected by Express Scripts for reimbursement but other US health insurers will accept it, say the analysts.

Barak Rosen and Assaf Tuchmeir Photo: Eyal Izhar Israel Canada buys Tel Aviv seafront lot

An approved urban building plan that applies to the entire site provides for construction of a 22-floor tower.

Wed: Teva slump drags down TASE

Teva fell sharply after a reimbursement snub as energy stocks exacerbated losses on the market.

Novartis to invest in $60m Gamida Cell Nasdaq IPO

The Israeli stem cell cancer therapy developer will hold the offering at a company valuation of $275 million.

Teva Photo: Reuters Ammar Awad Teva falls on migraine drug indemnity snub

Express Scripts has endorsed coverage of competing migraine drugs made by Amgen and Eli Lilly.

Arik Pinto  photo: Tamar Matsafi Hapoalim to record NIS 119m profit from Clal Insurance sale

Under an agreement between the bank and IDB, first refusal rights will expire if there is no deal by November 11.

Tel Aviv Stock Exchange Photo: Eli Yizhar Australia's ASX seeks dual-listing agreement with TASE

The Australian Securities Exchange has attracted 18 early-stage Israeli high-tech companies.

Doron Gerstel Photo: Eyal Yitzhar Perion social campaign platform awarded Google certification

MakeMereach is a platform that enables agencies and advertisers to fully optimize their social campaigns.

Osnat Segev-Harel Photo: PR Eos Venture Partners to invest in Israeli insurtech

The $100 million fund will invest in early stage insurtech startups.

Team8 Photo: London Stock Exchange Temasek buys Israeli cybersecurity co Sygnia for $250m

The Singapore investment company is acquiring the Tel Aviv-based cybersecurity consulting startup.

Shekel Photo: ASAP Creative Shekel weakens after Sept CPI

Many analysts including Goldman Sachs do not see an interest rate hike in Israel this year.

Energean rig Photo: Company website Energean set to list on TASE by end of October

The Greek energy exploration company's shares will be included in the Tel Aviv 90 Index; it will not issue new shares.

Bank Hapoalim Photo: Tamar Matsafi Hapoalim mulls selling Clal Insurance stake

The bank is believed to be considering the sale, in view of the recent rise in Clal Insurance's share price.

LYFE project, Bnei Brak image: Studio 84 Ashtrom sees NIS 900m revenue from LYFE project construction

Ashtrom will construct two office and commercial towers on the Bnei Brak site it owns jointly with Dan Bus Company.

El Al plane Photo: Tamar Matsafi El Al management approves agreement with pilots

The El Al board of directors approved the new labor agreement two weeks before new flight time limitation regulations are scheduled to take effect.

Manchester's Midland hotel Fattal buys Manchester's iconic Midland hotel

The Israeli hotel chain will rent and manage The Midland for 35 years.

Reshet-Channel 10 merger  image: Shutterstock Reshet shareholders cancel merger with Channel 10

The shareholders place the blame for the cancellation squarely on the Second Broadcasting Authority.

Harel Wiesel photo; Eyal Izhar External investigator: No sexual harassment at Fox

"No fault was found in the company's behavior and that of its executives in these areas."

Leon Koffler  photo: PR Amir Marketing, Leon Koffler investing in BOL Pharma

BOL produces and markets cannabis for the Israeli market.

Karnit Flug  photo: Eyal Izhar Flug to ease restrictions on non-bank credit

Non-banking companies will be able raise up to NIS 20 billion.

Copaxone Teva loses another Copaxone patents case

The US Court of Appeals for the Federal Circuit upheld a 2017 decision by a Delaware court canceling four patents on the 40 mg version of Teva's blockbuster multiple sclerosis treatment.

Israel Chemicals Israel Chemicals signs new potash contracts in China

The price is $60 per tonne higher than in Israel Chemicals' previous contracts with Chinese customers.

El Al   photo: Sivan Farag Israeli airlines' winter schedules still at risk

The Ministry of Foreign affairs is adamant that it will stop employing flight security personnel overseas in January.

SolarEdge panels Photo: PR SolarEdge buys majority stake in battery co Kokam for $88m

The Israeli solar energy company is acquiring a 75% stake in the Korean lithium-ion battery provider.

KZEN founders Photo: PR Israeli crypto-wallet co KZen Networks raises $4m

The beta trial of the Israeli company's app will begin in the coming weeks,

Dr Anat Cohen-Dayag Photo: Kfir Ziv BMS invests $12m in Compugen for tumor collaboration

The companies have entered into a clinical trial collaboration to evaluate Compugen’s COM701 with BMS's PD-1 immune checkpoint inhibitor Opdivo, in patients with advanced solid tumors.

Teva Photo: ASAP Creative Shutterstock Teva receives FDA nod for Rituxan biosimilar cancer drug

If the FDA approves CT-P10 for marketing, this will be the first biosimilar generic version of Rituxan.

Shekel Photo: Shutterstock Shekel weakens against dollar despite Trump's Fed remarks

President Donald Trump's criticism of US Fed policy puts into question its plan for four more rate hikes by the end of 2019.

Donald Trump  photo: Reuters World markets in turmoil after Trump attacks Fed

The Tel Aviv Stock Exchange is also sharply down after President Trump criticized the US Fed's interest rate hikes.

Shlomo Kramer  photo: PR Thoma Bravo buys cybersecurity co Imperva for $2.1b

US based Imperva was founded by three Israelis and has offices in Tel Aviv and Rehovot.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018